Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KontRASt-03
2023-506716-41-00Phase 2Completed
- Sponsor
- Novartis
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, open-label trial of opnurasib in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) (3 arms), sponsored by Novartis. Started Oct 2022; status: completed.
02
Drugs
opnurasib
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)colorectal cancer (CRC)
Beyond the preview
Go deeper on 2023-506716-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506716-41-00.